Do you want to read an article? Please log in or register.
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer
Genitourinary Cancer
Related content
ESMO 2025
Genitourinary Cancer
EMBARK: Enzalutamide plus leuprolide significantly improves OS in high-risk biochemically recurrent prostate cancer
Genitourinary Cancer
Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age
Eur J Cancer
Shore ND, De Giorgi U, Kalac M, Tang Y, Croitoru R, Rosales M, Huynh MJ, de Jong IJ, Evans CP, Carcano FM, Freedland SJ
doi: 10.1016/j.ejca.2025.116110
COMMENTED
Genitourinary Cancer
Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK Trial
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
J Urol
Shore ND, Gleave M, De Giorgi U, Rannikko A, Pieczonka CM, Sridharan S, Brasso K, Woo HH, Gómez Caamaño A, Saranchuk JW, Nordquist LT, Ferreira U, Tang Y, Rosbrook B, Haas GP, Rosales M, Zohren F, Tarazi J, Freedland SJ
doi: 10.1097/JU.0000000000004890
Genitourinary Cancer
Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary Endpoints
J Urol
Shore ND, De Giorgi U, Tutrone RF, Bailen JL, Roos EP, Kliment J, Marx G, Karsh LI, Ramirez-Backhaus M, Uchio EM, Supiot S, Tang Y, Rosbrook B, Haas GP, Rosales M, Zohren F, Tarazi J, Freedland SJ
doi: 10.1097/JU.0000000000004879
Genitourinary Cancer
Survival trend in metastatic prostate cancer two decades of real-world data on overall survival from Germany
Prostate Cancer Prostatic Dis
Sondermann M, Stehr A, Hirtsiefer C, Menzel V, Buttmann-Schweiger N, Flemming PW, Kraywinkel K, Thomas C, Boehm K
doi: 10.1038/s41391-026-01092-w
Genitourinary Cancer
Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer
Adv Ther
Bilen MA, Lowentritt B, Khilfeh I, Rossi C, Du S, Kinkead F, Diaz L, Pilon D, Ellis L, Shore ND
doi: 10.1007/s12325-025-03207-6
Genitourinary Cancer
Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Long-term Data from the SAKK 09/10 Randomised Phase 3 Trial
Eur Urol
Ghadjar P, Hayoz S, Zwahlen DR, Hölscher T, Arnold W, Polat B, Hildebrandt G, Hoffmann E, Plasswilm L, Papachristofilou A, Schär C, Sumila M, Zaugg K, Guckenberger M, Ost P, Reuter C, Bosetti DG, Khanfir K, Riesterer O, Beck M, Thalmann GN, Aebersold DM, Swiss Group for Clinical Cancer Research (SAKK)
doi: 10.1016/j.eururo.2025.12.020
Genitourinary Cancer
ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients
Eur Urol
Armstrong AJ, Petrylak DP, Shore ND, Szmulewitz RZ, Holzbeierlein J, Villers A, Alcaraz A, Alekseev B, Iguchi T, Gomez-Veiga F, Croitoru R, Wu R, Kalac M, Tang Y, Stenzl A, Azad AA
doi: 10.1016/j.eururo.2025.12.021
Genitourinary Cancer
Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer
Ann Oncol
Gillessen S, Gallardo E, Choudhury A, Saad F, Soares A, Loriot Y, McDermott R, Rodriguez-Vida A, Isaacsson Velho P, Nolè F, Cruz F, Roumeguere T, Daugaard G, Yamamura R, Bompas E, Maroto P, Veiga FG, Skoneczna I, Martins da Trindade K, Mavignier Carcano F, Lecouvet F, Coens C, Poncet C, Fournier B, Tombal B
doi: 10.1016/j.annonc.2026.02.009